Hutchings, M., Balarí, A. S., Albareda, F. B., Larsen, T., Corradini, P., Avigdor, A., Terol, M. J., Dominguez, A. R., Pinto, A., Skarbnik, A., Córdoba, R., Jørgensen, J., Zinzani, P. L., Gurion, R., Goldschmidt, N., Leung, W., Li, D., Relf, J., Kallemeijn, M. J., Sellam, G., Gritti, G. (2025). Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis. Blood. https://doi.org/10.1182/blood-2025-5510